600664 哈药股份
已收盘 02-06 15:00:00
资讯
新帖
简况
每周股票复盘:哈药股份(600664)Q3净利降35.35%,GNC中国拟降本增效
证券之星 · 21分钟前
每周股票复盘:哈药股份(600664)Q3净利降35.35%,GNC中国拟降本增效
哈药股份:2月5日接受机构调研,中金银海(香港)基金有限公司、中天汇鑫(北京)投资基金管理有限公司等多家机构参与
证券之星 · 02-06 19:01
哈药股份:2月5日接受机构调研,中金银海(香港)基金有限公司、中天汇鑫(北京)投资基金管理有限公司等多家机构参与
哈药股份:所属企业获得化学原料药上市申请批准通知书
新京报 · 02-05 16:22
哈药股份:所属企业获得化学原料药上市申请批准通知书
哈药股份(600664.SH)所属企业药品通过一致性评价
智通财经 · 02-04
哈药股份(600664.SH)所属企业药品通过一致性评价
哈药股份(600664.SH):蛋白琥珀酸铁口服溶液获得药品注册证书
智通财经 · 02-02
哈药股份(600664.SH):蛋白琥珀酸铁口服溶液获得药品注册证书
每周股票复盘:哈药股份(600664)2026年日常关联交易预计5,192.90万元
证券之星 · 02-01
每周股票复盘:哈药股份(600664)2026年日常关联交易预计5,192.90万元
哈药股份(600664)披露2026年度日常关联交易预计公告,1月26日股价上涨1.4%
证券之星 · 01-26
哈药股份(600664)披露2026年度日常关联交易预计公告,1月26日股价上涨1.4%
哈药股份(600664)公司公告变更质量控制复核人,1月21日股价下跌0.28%
证券之星 · 01-21
哈药股份(600664)公司公告变更质量控制复核人,1月21日股价下跌0.28%
哈药股份(600664)披露关于变更签字注册会计师、质量控制复核人的公告,1月7日股价下跌0.85%
证券之星 · 01-07
哈药股份(600664)披露关于变更签字注册会计师、质量控制复核人的公告,1月7日股价下跌0.85%
哈药股份拟修订公司章程 强化治理与可持续发展
中金财经 · 2025-12-25
哈药股份拟修订公司章程 强化治理与可持续发展
人民同泰最新公告:控股股东哈药股份计划减持不超1%公司股份
证券之星 · 2025-11-19
人民同泰最新公告:控股股东哈药股份计划减持不超1%公司股份
哈药股份(600664)2025年三季报简析:净利润同比下降35.35%
证券之星 · 2025-10-26
哈药股份(600664)2025年三季报简析:净利润同比下降35.35%
每周股票复盘:哈药股份(600664)获磷酸奥司他韦干混悬剂注册证
证券之星 · 2025-10-26
每周股票复盘:哈药股份(600664)获磷酸奥司他韦干混悬剂注册证
哈药股份(600664)9月30日股东户数9.81万户,较上期增加1.09%
证券之星 · 2025-10-24
哈药股份(600664)9月30日股东户数9.81万户,较上期增加1.09%
哈药股份(600664.SH)发布前三季度业绩,归母净利润3.29亿元,同比下降35.35%
智通财经 · 2025-10-24
哈药股份(600664.SH)发布前三季度业绩,归母净利润3.29亿元,同比下降35.35%
哈药股份最新公告:所属企业三精明水获得乳酸钙化学原料药上市申请批准通知书
证券之星 · 2025-10-20
哈药股份最新公告:所属企业三精明水获得乳酸钙化学原料药上市申请批准通知书
哈药股份最新公告:所属企业哈药六厂获得磷酸奥司他韦干混悬剂药品注册证书
证券之星 · 2025-10-20
哈药股份最新公告:所属企业哈药六厂获得磷酸奥司他韦干混悬剂药品注册证书
哈药股份(600664)披露控股股东部分股份解除质押及质押,10月14日股价上涨0.28%
证券之星 · 2025-10-14
哈药股份(600664)披露控股股东部分股份解除质押及质押,10月14日股价上涨0.28%
每周股票复盘:哈药股份(600664)控股股东质押股份延期购回
证券之星 · 2025-10-12
每周股票复盘:哈药股份(600664)控股股东质押股份延期购回
哈药股份控股股东6.88亿股质押延期 累计79%持股被质押
财中社 · 2025-10-10
哈药股份控股股东6.88亿股质押延期 累计79%持股被质押
加载更多
公司概况
公司名称:
哈药集团股份有限公司
所属行业:
医药制造业
上市日期:
1993-06-29
主营业务:
哈药集团股份有限公司的主营业务是医药研发与制造、批发与零售业务。公司的主要产品是钙铁锌口服液、复方葡萄糖酸钙口服溶液、葡萄糖酸锌口服溶液、阿莫西林胶囊、人促红素注射液、双黄连口服液、拉西地平片、注射用头孢曲松钠、祛风骨痛凝胶膏、健安喜Vitapak营养包、健安喜鱼油软胶囊、健安喜儿童液体钙镁锌、注射用青霉素钠、小儿氨酚黄那敏颗粒等。报告期内,公司屡获殊荣,“哈药”入选首批黑龙江省消费名品企业品牌名录;“世一堂”、“三精”入选黑龙江省消费名品成长企业名单;“三精”系列产品荣获“西鼎奖2024-2025年度中国药品零售市场畅销产品”;“护彤”系列产品荣获“西湖奖最受药店欢迎的明星单品”。
发行价格:
1.00
{"stockData":{"symbol":"600664","market":"SH","secType":"STK","nameCN":"哈药股份","latestPrice":3.52,"timestamp":1770361201000,"preClose":3.51,"halted":0,"volume":29042563,"delay":0,"changeRate":0.0028,"floatShares":2519000000,"shares":2519000000,"eps":0.1784,"marketStatus":"已收盘","change":0.01,"latestTime":"02-06 15:00:00","open":3.52,"high":3.56,"low":3.51,"amount":103000000,"amplitude":0.0142,"askPrice":3.53,"askSize":6315,"bidPrice":3.52,"bidSize":24625,"shortable":0,"etf":0,"ttmEps":0.1784,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":3.51,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":3.86,"lowLimit":3.16,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2518509876,"isCdr":false,"pbRate":1.57,"roa":"--","peRate":19.730942,"roe":"5.96%","epsLYR":0.25,"committee":-0.257836,"marketValue":8865000000,"turnoverRate":0.0115,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-02-09。","floatMarketCap":8865000000},"requestUrl":"/m/hq/s/600664","defaultTab":"news","newsList":[{"id":"2609178526","title":"每周股票复盘:哈药股份(600664)Q3净利降35.35%,GNC中国拟降本增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2609178526","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609178526?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:13","pubTimestamp":1770491590,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,哈药股份报收于3.52元,较上周的3.52元上涨0.0%。本周,哈药股份2月6日盘中最高价报3.56元。来自机构调研要点:GNC中国将聚焦电商全渠道建设,并推进降本增效以降低销售费用投入。业绩披露要点公司2025年前三季度利润总额为48,103.91万元,同比下降32.31%;归属于上市公司股东的净利润为32,859.45万元,同比下降35.35%。截至目前,国内共有11家企业该原料药登记状态为“A”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600664","BK0012","BK0028","BK0188"],"gpt_icon":0},{"id":"2609562672","title":"哈药股份:2月5日接受机构调研,中金银海(香港)基金有限公司、中天汇鑫(北京)投资基金管理有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2609562672","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609562672?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:01","pubTimestamp":1770375702,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年2月6日哈药股份发布公告称公司于2026年2月5日接受机构调研,中金银海(香港)基金有限公司、中天汇鑫(北京)投资基金管理有限公司、上海汇正财经顾问有限公司参与。三是紧盯市场动态,强化品牌价值,促进 GNC 中国业务合规、高质量发展。子公司已分别于 2023 年和 2024 年连续两年向母公司累计分红 4.03 亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600034275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600664","BK0239","BK0188","BK0028","BK0012"],"gpt_icon":0},{"id":"2609532268","title":"哈药股份:所属企业获得化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2609532268","media":"新京报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609532268?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:22","pubTimestamp":1770279720,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 2月5日,哈药股份公告,所属企业哈药集团三精明水药业有限公司收到国家药品监督管理局颁发的关于蛋白琥珀酸铁的《化学原料药上市申请批准通知书》【编号:2026YS00100】。蛋白琥珀酸铁是一种有机铁化合物,本品获得化学原料药上市申请批准通知书,表明该原料药已符合国家相关药品审评技术标准。国家药品监督管理局药品审评中心网站显示,截至本公告日,国内蛋白琥珀酸铁原料药登记状态为“A”的企业共有11家,包含哈药集团三精明水药业有限公司、济川药业集团有限公司等。","market":"us","thumbnail":"https://media.bjnews.com.cn/cover/2026/01/12/5674876761498789488.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/01/12/5674876761498789488.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1770277199129176.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1770277199129176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0188","600664","BK0028","BK0239","BK0012"],"gpt_icon":0},{"id":"2608353053","title":"哈药股份(600664.SH)所属企业药品通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2608353053","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608353053?lang=zh_cn&edition=full","pubTime":"2026-02-04 15:46","pubTimestamp":1770191173,"startTime":"0","endTime":"0","summary":"智通财经APP讯,哈药股份(600664.SH)公告,公司所属企业哈药集团制药总厂(简称“哈药总厂”)收到国家药品监督管理局颁发的关于注射用头孢哌酮钠舒巴坦钠(1:1)和注射用头孢哌酮钠舒巴坦钠(2:1)的《药品补充申请批准通知书》【编号:2026B00587、2026B00592、2026B00590、2026B00591】,以上两个药品共4个规格通过仿制药质量和疗效一致性评价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600664","BK0012","BK0028","BK0188"],"gpt_icon":0},{"id":"2608569328","title":"哈药股份(600664.SH):蛋白琥珀酸铁口服溶液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608569328","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608569328?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:02","pubTimestamp":1770019330,"startTime":"0","endTime":"0","summary":"智通财经APP讯,哈药股份(600664.SH)发布公告,近日,公司所属企业哈药集团中药二厂(简称“中药二厂”)收到国家药品监督管理局颁发的关于蛋白琥珀酸铁口服溶液的《药品注册证书》【编号:2026S00300】,本品获得批准注册。蛋白琥珀酸铁口服溶液为非处方药,用于治疗缺铁性贫血,包括由于铁摄入量不足或吸收障碍、慢性失血以及妊娠与哺乳期引起的缺铁性贫血。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"哈药股份(600664.SH):蛋白琥珀酸铁口服溶液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","600664","BK0028","BK0012"],"gpt_icon":0},{"id":"2608607068","title":"每周股票复盘:哈药股份(600664)2026年日常关联交易预计5,192.90万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608607068","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608607068?lang=zh_cn&edition=full","pubTime":"2026-02-01 04:12","pubTimestamp":1769890334,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总:哈药股份2026年度日常关联交易预计总额为5,192.90万元。哈药集团股份有限公司于2026年1月26日召开十届二十三次董事会,审议通过《关于公司2026年度日常关联交易预计的议案》,关联董事回避表决。2026年预计日常关联交易总额为5,192.90万元,主要包括向哈药集团生物疫苗有限公司等关联方销售产品、提供劳务,向GNC HOLDINGS, LLC采购产品及支付特许权使用费,以及向黑龙江省哈药公益基金会捐赠。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600664","BK0239","BK0028","BK0188","BK0012"],"gpt_icon":0},{"id":"2606124930","title":"哈药股份(600664)披露2026年度日常关联交易预计公告,1月26日股价上涨1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606124930","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606124930?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:39","pubTimestamp":1769438377,"startTime":"0","endTime":"0","summary":"近日,哈药集团股份有限公司披露《关于2026年度日常关联交易预计的公告》。公告显示,公司于2026年1月26日召开十届二十三次董事会,审议通过《关于公司2026年度日常关联交易预计的议案》,关联董事回避表决。2026年预计日常关联交易总额为5,192.90万元,主要包括向哈药集团生物疫苗有限公司等关联方销售产品、提供劳务,向GNC HOLDINGS, LLC采购产品及支付特许权使用费,以及向黑龙江省哈药公益基金会捐赠。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600036437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","600664","BK0239","BK0188"],"gpt_icon":0},{"id":"2605832464","title":"哈药股份(600664)公司公告变更质量控制复核人,1月21日股价下跌0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605832464","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605832464?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:33","pubTimestamp":1769005990,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘,哈药股份报收于3.52元,较前一交易日下跌0.28%,最新总市值为88.65亿元。近日,哈药集团股份有限公司发布公告称,因中证天通会计师事务所内部质量管理体系优化及合伙人轮岗计划,决定变更公司2025年度财务报告及内部控制审计项目的质量控制复核人。原质量控制复核人牛浩变更为毛宝林。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100041145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","600664","BK0188","BK0239"],"gpt_icon":0},{"id":"2601809760","title":"哈药股份(600664)披露关于变更签字注册会计师、质量控制复核人的公告,1月7日股价下跌0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601809760","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601809760?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:22","pubTimestamp":1767795742,"startTime":"0","endTime":"0","summary":"近日,哈药集团股份有限公司发布公告称,因中证天通会计师事务所内部工作调整,公司2025年度财务报告及内部控制审计项目的签字注册会计师和质量控制复核人发生变更。变更后,签字注册会计师为邢士军、谭丽,质量控制复核人为牛浩。公告显示,谭丽自2003年成为注册会计师,曾于2016至2018年为公司提供审计服务;牛浩自2021年成为注册会计师,近三年复核8家上市公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700038903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","600664","BK0028","BK0188"],"gpt_icon":0},{"id":"2594891822","title":"哈药股份拟修订公司章程 强化治理与可持续发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2594891822","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594891822?lang=zh_cn&edition=full","pubTime":"2025-12-25 10:48","pubTimestamp":1766630892,"startTime":"0","endTime":"0","summary":"中访网数据 哈药集团股份有限公司于2025年12月24日召开第十届董事会第二十二次会议,审议通过了关于修订《公司章程》的议案。 根据公告,修订内容涉及《公司章程》中的多个条款。 此次章程修订尚需提交公司股东大会审议批准。通过本次修订,哈药股份旨在进一步规范公司治理运作,同时积极响应监管机构对上市公司加强ESG管理的倡导,将可持续发展提升至公司战略层面,以推动长期稳健发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251225/31891480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK0012","600664","BK0028","BK0188"],"gpt_icon":0},{"id":"2584486029","title":"人民同泰最新公告:控股股东哈药股份计划减持不超1%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2584486029","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584486029?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:10","pubTimestamp":1763550606,"startTime":"0","endTime":"0","summary":"人民同泰(600829.SH)公告称,控股股东哈药集团股份有限公司持有公司股份433,894,354股,占公司总股本的74.82%,因经营需要,计划自公告披露之日起15个交易日后的3个月内,通过集中竞价交易方式减持不超过579.88万股的公司股份,占公司总股本比例不超过1%。减持期间为2025年12月11日至2026年3月10日。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900033284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","600664","BK0250","BK0028","BK0188","600829"],"gpt_icon":0},{"id":"2578808683","title":"哈药股份(600664)2025年三季报简析:净利润同比下降35.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578808683","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578808683?lang=zh_cn&edition=full","pubTime":"2025-10-26 06:02","pubTimestamp":1761429748,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期哈药股份发布2025年三季报。根据财报显示,哈药股份净利润同比下降35.35%。截至本报告期末,公司营业总收入120.21亿元,同比下降1.92%,归母净利润3.29亿元,同比下降35.35%。按单季度数据看,第三季度营业总收入38.97亿元,同比下降5.29%,第三季度归母净利润6888.93万元,同比下降58.22%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600664"],"gpt_icon":0},{"id":"2578071295","title":"每周股票复盘:哈药股份(600664)获磷酸奥司他韦干混悬剂注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2578071295","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578071295?lang=zh_cn&edition=full","pubTime":"2025-10-26 03:54","pubTimestamp":1761422054,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘,哈药股份报收于3.71元,较上周的3.64元上涨1.92%。股本股东变化股东户数变动截至2025年9月30日,哈药股份股东户数为9.81万户,较6月30日增加1060户,增幅1.09%。目前国内共有42个磷酸奥司他韦干混悬剂批准文号(含本次)和2个进口文号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600664","BK0239","BK0012"],"gpt_icon":0},{"id":"2577596274","title":"哈药股份(600664)9月30日股东户数9.81万户,较上期增加1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577596274","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577596274?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:07","pubTimestamp":1761296834,"startTime":"0","endTime":"0","summary":"证券之星消息,近日哈药股份披露,截至2025年9月30日公司股东户数为9.81万户,较6月30日增加1060.0户,增幅为1.09%。在化学制药行业个股中,哈药股份股东户数高于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.23万户。从股价来看,2025年6月30日至2025年9月30日,哈药股份区间跌幅为2.99%,在此期间股东户数增加1060.0户,增幅为1.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400029886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","600664","BK0239","BK0012"],"gpt_icon":0},{"id":"2577951115","title":"哈药股份(600664.SH)发布前三季度业绩,归母净利润3.29亿元,同比下降35.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577951115","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577951115?lang=zh_cn&edition=full","pubTime":"2025-10-24 16:38","pubTimestamp":1761295127,"startTime":"0","endTime":"0","summary":"智通财经APP讯,哈药股份(600664.SH)披露2025年第三季度报告,公司前三季度实现营收120.21亿元,同比下降1.92%;归母净利润3.29亿元,同比下降35.35%;扣非净利润2.89亿元,同比下降38.56%;基本每股收益0.13元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"哈药股份(600664.SH)发布前三季度业绩,归母净利润3.29亿元,同比下降35.35%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600664"],"gpt_icon":0},{"id":"2576536834","title":"哈药股份最新公告:所属企业三精明水获得乳酸钙化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2576536834","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576536834?lang=zh_cn&edition=full","pubTime":"2025-10-20 16:58","pubTimestamp":1760950701,"startTime":"0","endTime":"0","summary":"哈药股份公告称,公司所属企业哈药集团三精明水药业有限公司收到国家药品监督管理局颁发的关于乳酸钙的《化学原料药上市申请批准通知书》。乳酸钙主要用作药品制剂中的钙补充剂,此次获批表明该原料药已符合国家相关药品审评技术标准。截至公告日,国内乳酸钙原料药登记状态为“A”的企业共有6家,包括哈药集团三精明水药业有限公司。公司对乳酸钙原料药研发项目已投入研发费用合计约人民币657.89万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000020708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600664","BK0188","BK0239","BK0028","BK0012"],"gpt_icon":0},{"id":"2576834328","title":"哈药股份最新公告:所属企业哈药六厂获得磷酸奥司他韦干混悬剂药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2576834328","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576834328?lang=zh_cn&edition=full","pubTime":"2025-10-20 16:58","pubTimestamp":1760950689,"startTime":"0","endTime":"0","summary":"哈药股份(600664.SH)公告称,所属企业哈药集团制药六厂收到国家药品监督管理局颁发的磷酸奥司他韦干混悬剂的《药品注册证书》。该药品用于2周龄及以上年龄患者的甲型和乙型流感治疗和1岁及以上年龄人群的甲型和乙型流感预防。截至公告日,国内磷酸奥司他韦干混悬剂共有42个国内药品批准文号、2个进口药品批准文号。公司已为该项目投入研发费用约人民币2,217.50万元。该证书的获得丰富了公司产品种类,有利于优化公司产品布局,但药品销售受多方面因素影响,存在不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000020709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600664","BK0188","BK0012","BK0239","BK0028"],"gpt_icon":0},{"id":"2575981152","title":"哈药股份(600664)披露控股股东部分股份解除质押及质押,10月14日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575981152","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575981152?lang=zh_cn&edition=full","pubTime":"2025-10-14 17:25","pubTimestamp":1760433931,"startTime":"0","endTime":"0","summary":"近日,哈药集团股份有限公司发布关于控股股东部分股份解除质押及质押的公告。公告显示,公司控股股东哈药集团有限公司持有公司股份1,173,237,023股,占总股本的46.58%。本次解除质押股份287,581,686股,占其所持股份比例24.51%,占公司总股本比例11.42%,解除质押时间为2025年10月10日。本次质押后,哈药集团累计质押股份844,275,562股,占其所持股份比例71.96%,占公司总股本比例33.52%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400054185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","600664","BK0028","BK0239"],"gpt_icon":0},{"id":"2574468472","title":"每周股票复盘:哈药股份(600664)控股股东质押股份延期购回","url":"https://stock-news.laohu8.com/highlight/detail?id=2574468472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574468472?lang=zh_cn&edition=full","pubTime":"2025-10-12 03:22","pubTimestamp":1760210536,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘,哈药股份报收于3.64元,较上周的3.57元上涨1.96%。本周,哈药股份10月10日盘中最高价报3.64元。本次质押延期购回股份数688,021,638股,占其所持股份58.64%,占公司总股本27.32%,质押融资用于偿还债务、收购资产等,质权人为中国银行股份有限公司澳门分行,质押到期日由2025年10月6日延期至2025年11月7日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600664","BK0028","BK0012"],"gpt_icon":0},{"id":"2574178236","title":"哈药股份控股股东6.88亿股质押延期 累计79%持股被质押","url":"https://stock-news.laohu8.com/highlight/detail?id=2574178236","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574178236?lang=zh_cn&edition=full","pubTime":"2025-10-10 18:55","pubTimestamp":1760093700,"startTime":"0","endTime":"0","summary":"10月10日,哈药股份(600664)发布公告,控股股东哈药集团有限公司持有的6.88亿股质押股份延期购回,占其所持股份的58.64%及公司总股本的27.32%;截至公告披露日,哈药集团累计质押股份9.27亿股,占其所持股份的79.00%及公司总股本的36.80%。 2025年中期,哈药股份实现收入81.25亿元,归母净利润2.60亿元。(文章来源:财中社)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-10/doc-inftmhci1289386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600664","BK0012","BK0239","BK0028","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770492814860,"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0057},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.102},{"period":"1year","weight":-0.0688},{"period":"ytd","weight":0.0203}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"哈药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"98127人(较上一季度增加1.09%)","perCapita":"25665股","listingDate":"1993-06-29","address":"黑龙江省哈尔滨市呼兰区利民开发区利民西四大街68号","registeredCapital":"251850万元","survey":" 哈药集团股份有限公司的主营业务是医药研发与制造、批发与零售业务。公司的主要产品是钙铁锌口服液、复方葡萄糖酸钙口服溶液、葡萄糖酸锌口服溶液、阿莫西林胶囊、人促红素注射液、双黄连口服液、拉西地平片、注射用头孢曲松钠、祛风骨痛凝胶膏、健安喜Vitapak营养包、健安喜鱼油软胶囊、健安喜儿童液体钙镁锌、注射用青霉素钠、小儿氨酚黄那敏颗粒等。报告期内,公司屡获殊荣,“哈药”入选首批黑龙江省消费名品企业品牌名录;“世一堂”、“三精”入选黑龙江省消费名品成长企业名单;“三精”系列产品荣获“西鼎奖2024-2025年度中国药品零售市场畅销产品”;“护彤”系列产品荣获“西湖奖最受药店欢迎的明星单品”。","listedPrice":1},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"哈药股份(600664)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供哈药股份(600664)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"哈药股份,600664,哈药股份股票,哈药股份股票老虎,哈药股份股票老虎国际,哈药股份行情,哈药股份股票行情,哈药股份股价,哈药股份股市,哈药股份股票价格,哈药股份股票交易,哈药股份股票购买,哈药股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"哈药股份(600664)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供哈药股份(600664)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}